Restoring America

Conservative values, National renewal

Let Medicare cover weight loss drugs to make America healthy

Published



Despite his historic wariness of the pharmaceutical industry, Robert F. Kennedy Jr.’s stance toward weight-loss drugs appears to be softening.

In December 2024, President Donald Trump’s nominee to lead the Department of Health and Human Services asserted that GLP-1 medications such as Ozempic and Mounjaro “have a place” in treating obesity. In his recent Senate confirmation hearings, Kennedy touted the effectiveness of GLP-1s, calling them “miracle drugs.” He’s right — just ask George Barlow.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.